Zeta CD34 Antibody. Zeta’s recombinant mouse antibody recognizes CD34, a single chain transmembrane glycoprotein, which is selectively expressed on human lymphoid and myeloid hematopoietic progenitor cells. Staining for CD34 has been used to measure angiogenesis, which reportedly predicts tumor recurrence.
CD34 is a marker of vascular endothelial cells and is sensitive but not specific marker for neoangiogenesis. CD34 can mediate attachment of hematopoietic stem cells to bone marrow extracellular matrix or directly to stromal cells, although specific function is unknown. CD34 is helpful to distinguish liver lesions versus hepatocellular carcinoma and for screening marker to differentiate between soft tissue neoplasms. CD34 is a marker for hematopoietic progenitor cells.
CD34 can be used in dermatopathology to distinguish CD34+ dermal neoplasms, such as Kaposi sarcoma (CD34+), dermatofibrosarcoma protuberans (DSFP) (CD34+) and epithelioid sarcoma (often CD34+) from dermatofibroma (CD34-). CD34 can be used to distinguish solitary fibrous tumor (CD34+) from desmoplastic mesothelioma (CD34-) and to distinguish hemangiopericytoma (CD34+) from endometrial stromal sarcoma (CD34-).
In hematopathology, CD34 can be used to distinguish lymphocyte rich thymoma (CD34+ cells) from T cell acute lymphoblastic leukemia (T ALL, CD34-), to quantify and purify lymphohematopoietic stem cell and progenitor cells for research and for clinical bone marrow transplantation, and to identify blasts in general and in hypoplastic marrows.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.